InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,498.00
(
0.28%
)
US TECH 100
19,341.99
(
0.40%
)
Dow Jones
39,224.82
(
0.16%
)
Brent Oil
85.01
(
-0.47%
)
Bitcoin
61,039.36
(
-0.93%
)
Post# of 252413
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119944
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: InTheTrenches post# 96577

Tuesday, 06/01/2010 7:38:34 AM

Tuesday, June 01, 2010 7:38:34 AM

Post# of 252413
The point of Rick Shea’s comment is that a non-interchangeable generic Lovenox from Teva (or anyone else) does not count as a second generic Lovenox in the marketplace in the contractual formula that determines how much MNTA gets paid by NVS. In other words, if the FDA ends up approving an interchangeable generic from NVS/MNTA and a non-interchangeable generic from Teva, the economics for MNTA are just as good as the case where NVS/MNTA gets approved and Teva gets rejected.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up